Data compiled by Redley Lamar · ChainSifter Intelligence
0Suppliers
5Customers
3Debt Items
13Related Chains
Source-Backed Evidence Depth
Aldeyra Therapeutics, Inc. (ALDX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
1Distinct source URLs
6High confidence
0.807Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Aldeyra Therapeutics, Inc. Suppliers
No suppliers on recordAldeyra Therapeutics, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.
Reciprocal relationship from ABBV graph: Reciprocal relationship from ALDX graph: Outside of the United States, the Company would be eligible to receive tiered royalties on net sales of reproxalap.
DANFORTH-GLOBAL-INC
DANFORTH-GLOBAL-INC
62%
to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or …
FACEBOOK-IRELAND-LIMITED
FACEBOOK-IRELAND-LIMITED
62%
the EU. Transfer mechanisms have also been subject to various legal challenges. In particular, on July 16, 2020, the Court of Justice of the European Union, in the case of Data Protection Commissione…
HELIO-VISION-INC
HELIO-VISION-INC
62%
financial condition, and that may include, among other things: • the effect of the acquisition on our financial and strategic position and reputation; • the failure of an acquisition to result in exp…
Aldeyra Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ALDX-DEBT
Debt stack $15.3M
90%
Market cache reports total debt of $15.3M.
ALDX-DEBT-7670
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2014-12-31.
ALDX-DEBT-7669
Warrants outstanding: 211528
90%
xbrl warrant detail from xbrl 2018-12-31.
Aldeyra Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Aldeyra Therapeutics, Inc..
Aldeyra Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ALDX-OWNER-KNOLL-CAPITAL-MANAGEMENT-LLC
Knoll Capital Management, LLC
90%
13F overlay lists Knoll Capital Management, LLC as top holder; 125 tracked holders.
Aldeyra Therapeutics, Inc. Extended Supply Chain Network
